Inventors:
William Colby Brown - Cleveland Heights OH, US
Richard W. Heidebrecht - Brookline MA, US
Jason Brubaker - Cambridge MA, US
Christian Fischer - Natick MA, US
John T. Hendrix - Charlottesville VA, US
Elizabeth H. Kelley - Lynnfield MA, US
Rachel N. MacCoss - Brookline MA, US
Joey L. Methot - Westwood MA, US
Thomas Miller - Brookline MA, US
Karin M. Otte - Natick MA, US
Phieng Siliphaivanh - Newton MA, US
Thomas Reger - Lansdale PA, US
Peter D. Williams - Harleyville PA, US
Catherine M. Wiscount - Allentown PA, US
International Classification:
C07D 231/20, C07D 403/12, A61K 31/4155, C07D 401/12, A61K 31/4439, A61K 31/454, A61K 31/506, C07D 401/04, C07D 405/12, C07D 413/12, A61K 31/4245, A61K 31/422, A61K 31/5377, C07D 491/113, A61K 31/438, A61K 31/496, C07D 413/14, A61P 25/28, A61K 31/415
US Classification:
5142365, 5483661, 514407, 5483641, 5462761, 514341, 546211, 514326, 544316, 514274, 5483657, 548143, 514364, 548236, 514374, 544140, 546 19, 514278, 544371, 51425405
Abstract:
The invention encompasses a novel class of diaryl ether derivatives which inhibit the processing of APP by the putative γ-secretase while sparing Notch signaling pathway, and thus are useful in the treatment or prevention of Alzheimer's disease without the development of Notch inhibition mediated gastrointestinal issues. Pharmaceutical compositions and methods of use are also included.